MedDataX Logo

Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer

NCT05366153 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 748

Last updated 2025-12-04

No results posted yet for this study

Summary

REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy \>5 years ago.

Conditions

  • Coronary Artery Disease

Interventions

DIAGNOSTIC_TEST

Coronary CT

Screening/Management Plan

Sponsors & Collaborators

  • Western Health, Australia

    collaborator OTHER_GOV

  • Northern Hospital, Australia

    collaborator OTHER

  • Menzies Institute for Medical Research

    collaborator OTHER

  • Peter MacCallum Cancer Centre, Australia

    collaborator OTHER

  • The Alfred

    collaborator OTHER

  • Baker Heart and Diabetes Institute

    lead OTHER

Principal Investigators

  • Tom Marwick, MBBS,PhD,MPH · Baker Heart and Diabetes Institute

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-18
Primary Completion
2026-05-31
Completion
2026-05-31

Countries

  • Australia

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05366153 on ClinicalTrials.gov